CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES
What was lobbied
12 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Support full funding across HHS departments
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Copyright/Patent/Trademark CPT
Support protection of the Bayh-Dole Act and tech transfer process Support transferable exclusivity extensions to incentivize novel antibiotic and rare disease R&D Oppose legislative proposal to reform Patent system and Intellectual Property issues impacting the life sciences ecosystem
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Manufacturing MAN
Support robust domestic supply chain development and manufacturing ecosystem
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Small Business SMB
Support permanent re-authorization of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Science/Technology SCI
Support national strategy and federal privacy framework to bolster infrastructure for artificial intelligence in health care
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Tariff (miscellaneous tariff bills) TAR
Oppose tariffs that would negatively impact the bio-pharmaceutical and medical device industries
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Trade (domestic/foreign) TRD
Oppose Most Favored Nations Executive Order Submitted comments with regards to the Commerce Department's Section 232 Investigation on Medical Equipment
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Labor Issues/Antitrust/Workplace LBR
Educate policymakers and regulators on the unique role of mergers and acquisitions in the life sciences industry
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Health Issues HCR
Support diversity in clinical trial policy Oppose legislation that expands Medicare Drug Pricing Negotiation Program (MDPNP) Support bipartisan effort to address health care workforce shortage Support incentives for antimicrobial resistance development Support legislation that applies additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans Support legislation to prohibit pharmacy benefit managers (PBMs) from linking rebates paid by manufacturers to the list price of a drug and instead implement a flat service fee paid to PBMs Educate Congress on the current state of artificial intelligence in health care and the current regulatory landscape Oppose cap on indirect costs for NIH administered grants Support electronic labeling for all medical devices, regardless of setting of use or the intended user
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Medicare/Medicaid MMM
Support capping Medicare beneficiary out of pocket costs Oppose legislation to narrow the exclusion for orphan drugs under the MDPNP Support legislation to bring parity to small molecules and biologics with regards to when they qualify for negotiation under the MDPNP Support legislation providing Medicare coverage for anti-obesity medication
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Taxation/Internal Revenue Code TAX
Support R&D and NOL tax incentives Support full restoration of the Orphan Drug Tax Credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Medical/Disease Research/Clinical Labs MED
Support legislation to provide immediate coverage for FDA designated breakthrough medical devices Support legislation proposing coverage for multi-cancer screening Support timely re-authorization of the FDA Pediatric Rare Disease Priority Review Voucher program Support robust funding for the NIH in FY2025 appropriations
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN ROGERS | — |
| ANTHONY THEISSEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.